Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Davidson

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Chemmedchem|February 3, 2025
Structure-Atropisomer Stability Relationship in Selective MCL-1 InhibitorsSzabolcs Sipos, Barbara Balazs, Tamas Gati, et al.
The Clinical Biochemist. Reviews|February 2, 2006
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statementNagesh Anavekar, Renze Bais, Shane Carney, et al.
ACS Omega|September 9, 2021
The Effect of Core Replacement on S64315, a Selective MCL-1 Inhibitor, and Its AnaloguesSzabolcs Sipos, Balázs Bálint, Zoltán B Szabó, et al.
Journal of Medicinal Chemistry|March 6, 2026
Exploiting a Cryptic Pocket in DsbA through Structure-Guided Parallel Synthesis and Direct-to-Biology ScreeningYildiz Tasdan, Gautham R Balaji, James Davidson, et al.
ACS Omega|August 29, 2019
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1James B Murray, James Davidson, Ijen Chen, et al.
Journal of Medicinal Chemistry|July 25, 2019
Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular ActivityZoltan Szlávik, Levente Ondi, Márton Csékei, et al.
Journal of Medicinal Chemistry|November 4, 2020
Discovery of S64315, a Potent and Selective Mcl-1 InhibitorZoltan Szlavik, Marton Csekei, Attila Paczal, et al.
Journal of Medicinal Chemistry|June 12, 2026
Structure-Based Discovery of Potent BCL-XL Inhibitors through RescaffoldingMatyas Pal Timari, Attila Paczal, Andras Herner, et al.
Thorax|May 9, 2022
COVID-19-related changes in outpatient CPAP setup pathways for OSA are linked with decreased 30-day CPAP usageChris D Turnbull, Martin Allen, Jennifer Appleby, et al.
Oncotarget|May 8, 2018
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growthPatrick Casara, James Davidson, Audrey Claperon, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Chemmedchem|February 3, 2025
Structure-Atropisomer Stability Relationship in Selective MCL-1 InhibitorsSzabolcs Sipos, Barbara Balazs, Tamas Gati, et al.
The Clinical Biochemist. Reviews|February 2, 2006
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statementNagesh Anavekar, Renze Bais, Shane Carney, et al.
ACS Omega|September 9, 2021
The Effect of Core Replacement on S64315, a Selective MCL-1 Inhibitor, and Its AnaloguesSzabolcs Sipos, Balázs Bálint, Zoltán B Szabó, et al.
Journal of Medicinal Chemistry|March 6, 2026
Exploiting a Cryptic Pocket in DsbA through Structure-Guided Parallel Synthesis and Direct-to-Biology ScreeningYildiz Tasdan, Gautham R Balaji, James Davidson, et al.
ACS Omega|August 29, 2019
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1James B Murray, James Davidson, Ijen Chen, et al.
Journal of Medicinal Chemistry|July 25, 2019
Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular ActivityZoltan Szlávik, Levente Ondi, Márton Csékei, et al.
Journal of Medicinal Chemistry|November 4, 2020
Discovery of S64315, a Potent and Selective Mcl-1 InhibitorZoltan Szlavik, Marton Csekei, Attila Paczal, et al.
Journal of Medicinal Chemistry|June 12, 2026
Structure-Based Discovery of Potent BCL-XL Inhibitors through RescaffoldingMatyas Pal Timari, Attila Paczal, Andras Herner, et al.
Thorax|May 9, 2022
COVID-19-related changes in outpatient CPAP setup pathways for OSA are linked with decreased 30-day CPAP usageChris D Turnbull, Martin Allen, Jennifer Appleby, et al.
Oncotarget|May 8, 2018
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growthPatrick Casara, James Davidson, Audrey Claperon, et al.
Pageof 6